Evidence map›Paper›PMID 41065131›Full record

ReviewJournal of medical virology2025

The Sweet Aspects of Orthoflavivirus Treatment Design and Vaccine Development.

Ana C Alcalá, Michelle Gutiérrez, Juan E Ludert

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ana C AlcaláDepartment of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico.ORCID 0000-0002-6882-4765
Michelle GutiérrezDepartamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, México.ORCID 0000-0002-4478-2572
Juan E LudertDepartment of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (Cinvestav), Mexico City, Mexico.ORCID 0000-0003-4790-7681

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viruses in the genus Orthoflavivirus are among the most important human pathogens because of their significant public health impact. Many strategies have been proposed to develop specific or broad-spectrum treatments and preventive measures for these viral infections in humans. One of the most promising targets for developing treatments or vaccines is glycan molecules, found on both viral and host proteins, which are essential during the infectious cycle. This review examines various antiviral and immunization approaches focused on glycoproteins to fight orthoflavivirus infections.

Indexed as

Antiviral AgentsVaccine DevelopmentViral VaccinesAnimalsGlycoproteinsHumansAntiviral AgentsGlycoproteinsViral Vaccinesantiviral designdengueN‐glycosylationOrthoflavivirusvaccine developmentZika

Identifiers

PMID41065131
PMCPMC12509480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.